Principal Financial Group Inc. Sells 5,810 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Principal Financial Group Inc. decreased its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 26.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,799 shares of the company’s stock after selling 5,810 shares during the period. Principal Financial Group Inc.’s holdings in Taysha Gene Therapies were worth $32,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at about $1,018,000. Rhumbline Advisers bought a new stake in Taysha Gene Therapies in the second quarter worth $413,000. The Manufacturers Life Insurance Company lifted its position in Taysha Gene Therapies by 109.0% during the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock valued at $298,000 after purchasing an additional 69,487 shares during the last quarter. Scientech Research LLC purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter worth $97,000. Finally, SG Americas Securities LLC bought a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at about $129,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Down 8.3 %

NASDAQ TSHA opened at $1.88 on Wednesday. Taysha Gene Therapies, Inc. has a 52 week low of $1.19 and a 52 week high of $4.32. The company has a 50 day moving average price of $2.10 and a 200 day moving average price of $2.14. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The firm has a market cap of $385.29 million, a PE ratio of 2.98 and a beta of 0.95.

Analyst Upgrades and Downgrades

TSHA has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group increased their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Chardan Capital restated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Finally, JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.